Accumulus Synergy
Francisco Nogueira has extensive experience in the pharmaceutical industry, holding various leadership roles. Francisco began their career at Roche in 2000 as a Regulatory Leader/Director/Senior Director. In 2011, they joined Genentech as a Senior Group Director, responsible for global health authority submissions and system development functions. Francisco later served as the Senior Director of Regulatory Excellence & Chief of Staff, managing portfolio and resource management, project management, and budget for the Executive Vice President of Regulatory. Francisco also held roles as the Vice President of China Oncology Strategy and the Vice President of Life Cycle Leader for Alzheimer's disease at Genentech. In 2020, they became the Chief Executive Officer of Accumulus Synergy. Francisco has a proven track record of strategic leadership and driving organizational success in the pharmaceutical industry.
Francisco Nogueira received their Executive MBA from Rutgers Business School in 2006. Prior to that, they obtained a Bachelor of Arts degree in Geological and Earth Sciences/Geosciences from Kean University in 1996.
This person is not in any offices
Accumulus Synergy
Accumulus Synergy is a global, nonprofit industry association that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between life sciences organizations and and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the regulatory process by leveraging advanced technology and tools for data exchange. This will help reduce the cost of innovation and ultimately bring patients safe and effective medicines faster.